Log in to search using one of your social media accounts:

 

Teriparatide Bests Risedronate for Fracture Prevention in Severe Osteoporosis
Daily subcutaneous teriparatide prevents fractures more effectively than weekly oral risedronate, finds an international, industry-conducted study in the Lancet. Over 1300 postmenopausal women with... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 13, 2017 Category: Primary Care Source Type: news

Mecasermin [rDNA origin] (Increlex) Injection (Updated - Resolved)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - November 6, 2017 Category: Drugs & Pharmacology Source Type: news

Zomacton (Somatropin (rDNA origin) for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

Switching From Bisphosphonates to Teriparatide May Improve BMD in Women With RA Switching From Bisphosphonates to Teriparatide May Improve BMD in Women With RA
Switching women with rheumatoid arthritis (RA) from oral bisphosphonates to teriparatide increases bone mineral density (BMD) and trabecular bone score, according to a new report.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 18, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Nutropin Depot (Somatropin (rDNA origin) for Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 7, 2017 Category: Drugs & Pharmacology Source Type: news

Nutropin AQ (Somatropin (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 7, 2017 Category: Drugs & Pharmacology Source Type: news

Nutropin (Somatropin (rDNA origin) for Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 7, 2017 Category: Drugs & Pharmacology Source Type: news

Tev-Tropin (Somatropin, rDNA Origin, for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 3, 2017 Category: Drugs & Pharmacology Source Type: news

ICER review finds abaloparatide and teriparatide too costly
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2017 Category: Drugs & Pharmacology Source Type: news

Gattex (Teduglutide [rDNA origin] for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 19, 2017 Category: Drugs & Pharmacology Source Type: news

Comparison of osteoporosis treatments for improving bone mineral density
After teriparatide, osteoporosis treatment with denosumab yields higher additional bone mineral density gain, compared with bisphosphonates, according to data presented at the European Congress of Endocrinology 2017.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 31, 2017 Category: Endocrinology Source Type: news

Denosumab Ups BMD More Than Bisphosphates After Teriparatide Denosumab Ups BMD More Than Bisphosphates After Teriparatide
Use of denosumab after stopping teriparatide yields a greater increase in bone-mineral density in postmenopausal women with severe osteoporosis than bisphosphonates, according to a retrospective analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Bone Drug No Help in RA Erosions (CME/CE)
(MedPage Today) -- A year of treatment with teriparatide failed to repair damage (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 25, 2017 Category: Endocrinology Source Type: news

Forteo (Teriparatide (rDNA origin) Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 22, 2017 Category: Drugs & Pharmacology Source Type: news

​FDA approves Radius Health osteoporosis drug, but adds cancer warning
The FDA on Friday approved an osteoporosis drug made by Waltham-based Radius Health, but added a so-called "black box" warning that the treatment had increased the risk of bone cancer in rats. Radius (Nasdaq: RDUS) is hoping that abaloparatide, which will be sold under the brand name Tymlos, will eventually take on Forteo, an osteoporosis treatment sold by Eli Lilly (NYSE: LLY) that generated $1.5 billion in sales last year. Forteo has the same warning, which states that the drug increa sed the risk… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 28, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

​FDA approves Radius Health osteoporosis drug, but adds cancer warning
The FDA on Friday approved an osteoporosis drug made by Waltham-based Radius Health, but added a so-called "black box" warning that the treatment had increased the risk of bone cancer in rats. Radius (Nasdaq: RDUS) is hoping that abaloparatide, which will be sold under the brand name Tymlos, will eventually take on Forteo, an osteoporosis treatment sold by Eli Lilly (NYSE: LLY) that generated $1.5 billion in sales last year. Forteo has the same warning, which states that the drug increa sed the risk… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 28, 2017 Category: American Health Authors: Max Stendahl Source Type: news

Waltham-based Radius Health faces 3-month delay on drug approval
Radius Health suffered a setback Friday when the FDA delayed the potential approval of an osteoporosis drug that the Waltham biotech hopes will eventually take on Eli Lilly ’s $1.5 billion a year treatment Forteo. Radius (Nasdaq: RDUS) said in a statement Friday that the agency had moved its target approval date for the drug, called abaloparatide, from March 30 to June 30. According to Radius, regulators told the company on Thursday that they needed more time to rev iew additional information in… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 10, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

NovoLog Mix 70/30 (Insulin Aspart Protamine and Insulin Aspart (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2017 Category: Drugs & Pharmacology Source Type: news

Glide raises $4m for phase I trial of solid-dose teriparatide
Glide Technologies said today that it raised £3.2 million, or $4.0 million USD, in a round of financing. A number of existing investors contributed to the round, according to the Oxford-based company. Glide plans to use the funds to finish phase I trials this year for its solid dose formulation of a parathyroid hormone, teriparatide. Get the full story at our sister site, Drug Delivery Business News. The post Glide raises $4m for phase I trial of solid-dose teriparatide appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Funding Roundup Pharmaceuticals Wall Street Beat Glide Technologies Source Type: news

For Patients With Atypical Femur Fractures, Teriparatide Improves Bone Health For Patients With Atypical Femur Fractures, Teriparatide Improves Bone Health
Teriparatide may improve the bone health of patients with atypical femur fractures (AFFs) who've taken bisphosphonates, but doctors shouldn't depend on the drug to help heal the fractures, a new prospective study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2017 Category: Consumer Health News Tags: Orthopaedics News Source Type: news

New clinical trial to test drug combination to treat osteogenesis imperfecta
The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2017 Category: Pharmaceuticals Source Type: news

Increlex (Mecasermin [rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 5, 2017 Category: Drugs & Pharmacology Source Type: news

Exubera (Insulin Human [rDNA origin]) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 5, 2017 Category: Drugs & Pharmacology Source Type: news

Serostim (Somatropin (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news

Genotropin (Somatropin [rDNA origin]) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news

Humatrope (Somatropin rDNA Origin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news

Saxenda (Liraglutide [rDNA Origin]) Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 14, 2016 Category: Drugs & Pharmacology Source Type: news

EMA Okays LixiLan Plus Biosimilars for Osteoporosis and Diabetes EMA Okays LixiLan Plus Biosimilars for Osteoporosis and Diabetes
The EMA has given a green light to new diabetes medicines, including LixiLan and a new biosimilar version of insulin glargine, as well as two biosimilar versions of teriparatide for osteoporosis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 11, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

NovoLog (Insulin Aspart [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 10, 2016 Category: Drugs & Pharmacology Source Type: news

Omnitrope (Somatropin [ rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 31, 2016 Category: Drugs & Pharmacology Source Type: news

Calcitonin-salmon [rDNA origin] (Fortical) Nasal Spray (New - Discontinuation)
Updated Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - October 3, 2016 Category: Drugs & Pharmacology Source Type: news

Osteoporosis sufferers could benefit from new jab that can rebuild crumbly bones
In a clinical trial, four of 800 patients with osteoporosis had a spine fracture while taking new drug abaloparatide after 18 months compared with six taking a standard treatment, Forteo. (Source: the Mail online | Health)
Source: the Mail online | Health - September 19, 2016 Category: Consumer Health News Source Type: news

Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen ® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit
Novo Nordisk Inc. is recalling six batches of the GlucaGen ® HypoKit® in the U.S. due to two customer complaints from the UK and Portugal involving detached needles on the syringe with Sterile Water for Injection (SWFI). GlucaGen® HypoKit® is indicated for the treatment of severe hypoglycemia (low blood sugar) in patients with diabetes who are treated w ith insulin. A syringe with a detached needle cannot be used as prescribed. (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 9, 2016 Category: Food Science Source Type: news

Injected Drug May Help Fight Osteoporosis in Women
Abaloparatide appears to reduce fractures better than the current drug Forteo, researchers say Source: HealthDay Related MedlinePlus Pages: Osteoporosis, Women's Health (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 17, 2016 Category: Consumer Health News Source Type: news

Injected Drug May Help Fight Osteoporosis in Women
Abaloparatide appears to reduce fractures better than the current drug Forteo, researchers say (Source: WebMD Health)
Source: WebMD Health - August 16, 2016 Category: Consumer Health News Source Type: news

Forteo (teriparatide)
Title: Forteo (teriparatide)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/8/2016 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - August 8, 2016 Category: OBGYN Source Type: news

Lantus (Insulin Glargine [rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2016 Category: Drugs & Pharmacology Source Type: news

Romosozumab Tops Teriparatide in Phase 3 Osteoporosis Study Romosozumab Tops Teriparatide in Phase 3 Osteoporosis Study
Romosozumab, a novel investigational agent that both promotes bone formation and inhibits bone resorption, showed positive results at the hip and spine at 1 year. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 2, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide
In Phase 3 Open-Label STRUCTURE Study Postmenopausal Women With Osteoporosis Transitioning From Oral Bisphosphonates to Romosozumab Experienced Consistent and Significant Gains in Bone Mass and Estimated Strength Over Teriparatide THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced detailed Phase 3 results showing the investigational agent romosozumab demonstrated a statistically significant increase in hip bone mineral density (BMD) and strength compared with teriparatide in postmenopausal women with osteoporosis transitioning fr...
Source: Amgen News Release - April 1, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Radius Health files for approval of osteoporosis drug to rival Forteo
Radius Health on Wednesday announced that it’s submitted an application for U.S. approval of its drug for osteoporosis with which it hopes to take on the $1.5 billion a year drug, Forteo. It’s a milestone that’s been long in coming, starting with a late-stage trial of the drug that began in 2011 and ended up enrolling more than 2,400 patients in 30 sites across 20 countries. The study ended up showing the drug lowers bone fractures by 70 percent after a year-and-a-half, and showed the daily… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 30, 2016 Category: Biotechnology Authors: Don Seiffert Source Type: news

Combo Therapy vs Monotherapy for Postmenopausal OsteoporosisCombo Therapy vs Monotherapy for Postmenopausal Osteoporosis
The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Zorbtive (Somatropin rDNA Origin for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 14, 2016 Category: Drugs & Pharmacology Source Type: news

Teriparatide May Help Curb Hip FractureTeriparatide May Help Curb Hip Fracture
As well as improving bone mass and microstructure, teriparatide (Forteo, Lilly) specifically toughens fracture-prone hip areas, according to New York-based researchers. Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - March 8, 2016 Category: Orthopaedics Tags: Family Medicine/Primary Care News Source Type: news

TBRIA (calcitonin-salmon) for the Treatment of Postmenopausal Osteoporosis
TBRIA (calcitonin-salmon [rDNA origin] delayed release tablet) is the first oral recombinant salmon calcitonin, developed by Tarsa Therapeutics, for the treatment of postmenopausal osteoporosis. (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2015 Category: Pharmaceuticals Source Type: news

Teriparatide Manages Surgical HypoparathyroidismTeriparatide Manages Surgical Hypoparathyroidism
Use of teriparatide (parathyroid hormone 1-34) in patients with postsurgical hypoparathyroidism showed rapid increase in serum calcium and a decrease in phosphate, despite reduced calcium and vitamin D supplementation. Quality of life also improved. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 6, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Teriparatide to Denosumab Switch Helpful in OsteoporosisTeriparatide to Denosumab Switch Helpful in Osteoporosis
In postmenopausal osteoporotic women, changing from teriparatide to denosumab benefits bone mineral density (BMD) but switching from denosumab to teriparatide may result in bone loss, according to new research. Reuters Health Information (Source: Medscape ObGyn and Womens Health Headlines)
Source: Medscape ObGyn and Womens Health Headlines - July 15, 2015 Category: OBGYN Tags: Orthopaedics News Source Type: news

Zomacton (somatropin rDNA origin) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 2, 2015 Category: Drugs & Pharmacology Source Type: news

teriparatide (Forteo)
Title: teriparatide (Forteo)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/19/2015 12:00:00 AM (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - June 19, 2015 Category: OBGYN Source Type: news

teriparatide (Forteo)
Title: teriparatide (Forteo)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 6/19/2015 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - June 19, 2015 Category: Drugs & Pharmacology Source Type: news